
May 08, 2024
Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise that its wholly owned Canadian subsidiary, Mernova, continues to make strong operational progress.
Highlights:
- Additional product launches across various provinces in addition to those previously announced
- Agreement with Best Kind Edibles signed for manufacturing of cannabis edibles as an extension to existing product suite
- Q2 confirmed purchase orders of $1.3m to date, highlighting ongoing strength of Ritual brand at the midpoint of the quarter
- Purchase orders follow unaudited Q1 revenues of $1.75m and FY23 full year revenues of $6.9m
In recent weeks, Mernova has achieved further new product launches, in addition to those announced on 2 April 2024. These include:
- Manitoba
- Two new products listed, Sacred Sage 3.5g and Sacred Sage 3x0.5g
- Nova Scotia Liquor Commission
- French Cookies 12x0.5g pre rolls one time offer approved
- Ontario Cannabis Store
- Black Mamba 12x0.5g pre-rolls now approved
- New Brunswick
- Black Mamba / French Cookies / Halifax Sage combo pack approved
- Newfoundland
- 9 SKUs pending for June launch
- Prince Edward Island, Limited Edition Program for the following products
- French cookies 3.5g
- Halifax Sage 3.5g
- Black Mamba 3.5g
- Black Mamba / French Cookies / Halifax Sage combo pack
- Black Mamba / Sugar Bumb Punch pre rolls combo paclk
- Yukon Liquor Commission approved 6 new SKUs for launch in May 2024
- Grape Cream Cake pre rolls 3x0.5g, 7x0.5g, 10x0.5g and 12x0.5g formats
- Sugar Bomb Punch Vape 1.0g
- Black Mamba Bubble Has Infused Blunt 1x1.0g
These results indicate the demand for the Ritual brand’s growing suite of products and strains. As an update to the 2 April 2024 announcement, Mernova has now signed a supply agreement with Best Kind Edibles for manufacturing of cannabis edibles (2x5mg) which will launch in the fall of 2024. During Q2 to date, Mernova has received purchase orders for $1.3m (C$1.2m at current C$ to A$ of 1.11) of product. This strong start to the quarter follows unaudited Q1 revenues of $1.75m, and FY23 revenues of $6.9m.
Management commentary:
CEO and Managing Director, Mr William Lay said: “Mernova continues to deliver strong revenue figures and we are very proud of the team for their ongoing commitment to high quality cannabis. We look forward to generating further purchase orders as new products and formats become available.”
Click here for the full ASX Release
This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
ME1:AU
The Conversation (0)
05 October 2023
Melodiol Global Health
Global Portfolio of Strategic Cannabis and Plant-based Businesses
16 September
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
30 July
Psychedelics Market Update: H1 2025 in Review
The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
08 May
US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025
When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
03 March
Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia
Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...
18 February
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
23 January
Psychedelics Market Forecast: Top Trends for Psychedelics in 2025
The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks. While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00